Matches in Nanopublications for { ?s ?p "[Pathological samples of SCLC also expressed IGFBP-2 abundantly, as compared with NSCLC, and showed only rare (8%) IGFBP-2 promoter methylation, whereas the IGFBP-2 promoter was methylated in 71% of adenocarcinomas and 29% of squamous cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP526937.RAXfhq8LY2c3-Cd2IVwEtj8-wVchvOT1DPizBUMnuirDM130_assertion description "[Pathological samples of SCLC also expressed IGFBP-2 abundantly, as compared with NSCLC, and showed only rare (8%) IGFBP-2 promoter methylation, whereas the IGFBP-2 promoter was methylated in 71% of adenocarcinomas and 29% of squamous cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526937.RAXfhq8LY2c3-Cd2IVwEtj8-wVchvOT1DPizBUMnuirDM130_provenance.
- NP841811.RAm4cMxvrdD5j2PLdO6UQTuQy8v7tim2-ABNdsZj8yohk130_assertion description "[Pathological samples of SCLC also expressed IGFBP-2 abundantly, as compared with NSCLC, and showed only rare (8%) IGFBP-2 promoter methylation, whereas the IGFBP-2 promoter was methylated in 71% of adenocarcinomas and 29% of squamous cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP841811.RAm4cMxvrdD5j2PLdO6UQTuQy8v7tim2-ABNdsZj8yohk130_provenance.
- NP390847.RAyaCH6lThjmlJDrbmYH-Z9ZOlJMM8ROkaFgobSzEsLwg130_assertion description "[Pathological samples of SCLC also expressed IGFBP-2 abundantly, as compared with NSCLC, and showed only rare (8%) IGFBP-2 promoter methylation, whereas the IGFBP-2 promoter was methylated in 71% of adenocarcinomas and 29% of squamous cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP390847.RAyaCH6lThjmlJDrbmYH-Z9ZOlJMM8ROkaFgobSzEsLwg130_provenance.
- NP484743.RAUrdkJ-eoCQXiuaah4HVCQRq8S4BSxrG8fKMNViiVGYk130_assertion description "[Pathological samples of SCLC also expressed IGFBP-2 abundantly, as compared with NSCLC, and showed only rare (8%) IGFBP-2 promoter methylation, whereas the IGFBP-2 promoter was methylated in 71% of adenocarcinomas and 29% of squamous cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP484743.RAUrdkJ-eoCQXiuaah4HVCQRq8S4BSxrG8fKMNViiVGYk130_provenance.
- assertion description "[Pathological samples of SCLC also expressed IGFBP-2 abundantly, as compared with NSCLC, and showed only rare (8%) IGFBP-2 promoter methylation, whereas the IGFBP-2 promoter was methylated in 71% of adenocarcinomas and 29% of squamous cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Pathological samples of SCLC also expressed IGFBP-2 abundantly, as compared with NSCLC, and showed only rare (8%) IGFBP-2 promoter methylation, whereas the IGFBP-2 promoter was methylated in 71% of adenocarcinomas and 29% of squamous cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_assertion description "[Pathological samples of SCLC also expressed IGFBP-2 abundantly, as compared with NSCLC, and showed only rare (8%) IGFBP-2 promoter methylation, whereas the IGFBP-2 promoter was methylated in 71% of adenocarcinomas and 29% of squamous cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_provenance.
- NP757511.RAKw6vi3nClnNwtZ9WGkN8RtZ1_KI2PZMB7KUSLO39-0s130_assertion description "[Pathological samples of SCLC also expressed IGFBP-2 abundantly, as compared with NSCLC, and showed only rare (8%) IGFBP-2 promoter methylation, whereas the IGFBP-2 promoter was methylated in 71% of adenocarcinomas and 29% of squamous cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP757511.RAKw6vi3nClnNwtZ9WGkN8RtZ1_KI2PZMB7KUSLO39-0s130_provenance.
- NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_assertion description "[Pathological samples of SCLC also expressed IGFBP-2 abundantly, as compared with NSCLC, and showed only rare (8%) IGFBP-2 promoter methylation, whereas the IGFBP-2 promoter was methylated in 71% of adenocarcinomas and 29% of squamous cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_provenance.